Immunoinformatic strategy for developing multi-epitope subunit vaccine against Helicobacter pylori
Md Nahian1, Md Rasel Khan1, Fabiha Rahman1
1Department of Microbiology, Jagannath University, Dhaka, Bangladesh.
Plos One
|February 7, 2025
Summary
Computational methods designed two promising multi-epitope subunit vaccines against Helicobacter pylori infection. These novel vaccine candidates, HP_VaX_V1 and HP_VaX_V2, show strong immunogenicity and stability, offering a potential new strategy for controlling H. pylori.
Area of Science:
- Immunoinformatics
- Vaccine Design
- Computational Biology
Background:
- Helicobacter pylori infection causes significant gastric diseases, including ulcers and cancer.
- Current treatments are often ineffective due to bacterial resistance, and no vaccines are available.
- Computational approaches present a promising avenue for developing novel H. pylori vaccines.
Purpose of the Study:
- To design and evaluate novel multi-epitope subunit vaccine candidates against H. pylori using immunoinformatics.
- To identify stable, immunogenic, and non-allergenic vaccine constructs targeting key H. pylori antigens.
Main Methods:
- An immunoinformatic strategy combined B and T cell epitopes from BabA, CagA, and VacA proteins.
- 12 hypothetical vaccines were generated, with the top candidates (HP_VaX_V1, HP_VaX_V2) selected for further analysis.
- Evaluations included population coverage, molecular docking, immune simulations, and in silico cloning.
Main Results:
- Two vaccine candidates, HP_VaX_V1 and HP_VaX_V2, demonstrated high immunogenicity, stability, and non-allergenic properties.
- Molecular docking showed strong binding affinity to TLR-7 and TLR-8.
- Immune simulations predicted robust cell-mediated immunity and rapid antigen clearance.
Conclusions:
- The designed H. pylori vaccine candidates show significant potential for eliciting potent immune responses.
- In silico analyses support their viability for large-scale production.
- Laboratory validation is crucial to confirm the safety and immunogenicity of these proposed vaccines.
Related Concept Videos
Hybridoma Technology
14.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.0K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
320
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
320


